Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals reported FY25 standalone revenue from operations of ₹623.23 crore, up about 7.4% from ₹580.55 crore in FY24, while total income rose 5% to ₹645.71 crore. However, profitability took a hit — net profit fell 11.7% to ₹82.34 crore and EBITDA declined 7.7% to ₹123.97 crore, reflecting margin pressure from higher costs. EPS stood at ₹41.11 versus ₹46.58 last year. For Q4 FY25 alone, revenue grew sharply to ₹168.18 crore but net profit dropped to ₹11.58 crore from ₹18.60 crore. The board has recommended a dividend of ₹1.80 per share (18%) for FY25. The auditor issued an unmodified (clean) opinion, and the company remains net debt-free with operating cash flow improving strongly to ₹93.02 crore from ₹63.24 crore.
Mixed bag for shareholders — top-line growth is healthy and dividend is maintained, but the sharp fall in profits and EBITDA despite higher revenue signals margin compression that may concern investors. The company's ₹750 crore FY26 revenue target and improving operating cash flows are positives, but watch for cost discipline to restore profitability.